Biofourmis quietly parts company with CEO Rajput
pharmaphorum
SEPTEMBER 6, 2023
Biofourmis quietly parts company with CEO Rajput Phil.Taylor Wed, 06/09/2023 - 08:21 Bookmark this
pharmaphorum
SEPTEMBER 6, 2023
Biofourmis quietly parts company with CEO Rajput Phil.Taylor Wed, 06/09/2023 - 08:21 Bookmark this
STAT
AUGUST 30, 2023
A month after conducting significant layoffs, Biofourmis is out a CEO: Kuldeep Singh Rajput, one of the company’s founders, has quietly stepped down from his role. The Boston-based company was valued at $1.3 The Boston-based company was valued at $1.3 Continue to STAT+ to read the full story…
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
JANUARY 17, 2024
After visiting Biofourmis in Boston last year, OSP was impressed with the remote care the company could offer people from the comfort of their own homes.
Fierce Healthcare
FEBRUARY 25, 2024
LOS ANGELES—GE HealthCare is tapping virtual care company Biofourmis to extend the reach of patient monitoring tech from hospitals into patients’ homes. Announced at the ViVE 2024 conference on Monday, the collaboration leverages the combined capabilities of both companies to scale and deliver care-at-home solutions, executives said.
pharmaphorum
APRIL 26, 2022
Biofourmis has raised $300 million in fourth-round financing, sending its value rocketing to around $1.3 ” The new funding round takes the total raised to date by Biofourmis to $445 million, and was led by private equity firm General Atlantic, with support from existing investors including CVS Health. .”
pharmaphorum
AUGUST 11, 2022
One of the digital health sector’s latest unicorn companies – Biofourmis – has upscaled its recent fourth round financing, adding $20 million to the $300 million it raised in April. ” The post Digital health firm Biofourmis adds another $20m to its funding pot appeared first on. .
Outsourcing Pharma
OCTOBER 5, 2020
Companies like Biofourmis, THREAD and other virtual tech specialists have seen infusions of funds from investors bullish on decentralized clinical trials.
Let's personalize your content